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Abstract 
STAT5B, a specific member of the STAT family, is intimately associated with prostate tumor 
progression. While the full form of STAT5B is thought to promote tumor progression, a 
naturally occurring truncated isoform acts as a tumor suppressor. We previously demon-
strated that truncated STAT5 is generated by insertion of an alternatively spliced exon and 
results in the introduction of an early termination codon. Present approaches targeting STAT 
proteins based on inhibition of functional domains of STAT’s, such as DNA-binding, coop-
erative binding (protein-protein interaction), dimerization and phosphorylation will halt the 
action of the entire gene, both the proto-oncogenic and tumor suppressor functions of 
Stat5B.  
In this report we develop a new approach aimed at inhibiting the expression of full-length 
STAT5B (a proto-oncogene) while simultaneously enhancing the expression of STAT5∆B (a 
tumor suppressor). We have demonstrated the feasibility of using steric-blocking 
splice-switching oligonucleotides (SSOs) with a complimentary sequence to the targeted 
exon-intron boundary to enhance alternative intron/exon retention (up to 10%). The func-
tional effect of the intron/exon proportional tuning was validated by cell proliferation and 
clonogenic assays. The new scheme applies specific steric-blocking splice-switching oligonu-
cleotides and opens an opportunity for anti-tumor treatment as well as for the alteration of 
functional abilities of other STAT proteins. 
Key words: STAT proteins, RNA splicing, tumor suppressor, splice-switching oligonucleotides, 
cell-cycle progression. 
INTRODUCTION 
The STAT (Signal Transducer and Activator of 
Transcription) proteins are a family of cytoplasmic 
transcription factors that were originally identified in 
the mid-1990’s [1, 2]. To date, two predominant STAT 
isoforms have been identified: a full-length transcrip-
tion factor and a C-terminal truncated isoform lacking 
the transactivation domain [3, 4]. We previously de-
termined that the truncated STAT isoform is gener-
ated by retention of an alternatively spliced intron 
(Figure 1), resulting in the insertion of an early ter-
mination codon [4]. The resultant STAT5∆ protein, 
which lacks a transactivation domain, is then ex-
pressed. Phosphorylated STAT5∆ can translocate to 
the nucleus and bind to specific promoter sequences, 
thereby blocking the transcription of downstream 








truncated isoforms have been identified for STATs 1, 
3, 4, STAT 5a and 5b, and have been shown to be the 
product of alternative splicing [4-6]. While at least one 
group showed that STAT isoforms are a result of 
post-transcriptional proteolytic cleavage, it was noted 
that this event does not occur in vivo [6].  
Constitutive activation of STAT5 proteins has 
been demonstrated in many diverse human cancer 
cell lines and clinical tumors including those of the 
prostate [7-14]. A clear understanding of STAT5 func-
tion in vivo has been greatly hindered by the existence 
of two nearly identical genes, STAT5A and STAT5B, 
which share 93% homology at the amino acid level. 
An additional complication stems from the existence 
of naturally occurring C-terminal truncated domi-
nant-negative isoforms of STAT5 [4].  
Previous reports have suggested potentially di-
verse functions for STAT5 isoforms. Although, recent 
studies provide clear evidence that STAT5B, contrib-
utes to tumor progression in epithelial cancers [11, 13, 
15, 16], especially those of the prostate [11]. Specific 
activation of full-length STAT5B in epithelial cells 
representing invasive and metastatic prostate cancer 
has been previously demonstrated [11, 13]. This find-
ing is consistent with STAT5 being highly activated in 
high-grade human prostate cancers [9]. Increased ac-
tivation of STAT5 was also associated with increas-
ingly aggressive behavior of prostate cancer [9, 17]. In 
contrast, the naturally occurring dominant-negative 
truncated isoform STAT5∆B can block cell cycle pro-
gression and inhibit growth, invasive potential and 
clonogenic ability (hallmark of transformed and ma-
lignant potential [18]) of cancer cell lines [11, 17, 19, 
20]. Furthermore, we demonstrated that STAT5∆B 
could inhibit the growth of cancer cells in grafting 
studies in vivo [10, 11]. Thus, the previous research 
demonstrated role of dominant-negative form of 
STAT5B as tumor suppressor [11, 17, 19, 20], which 




Figure 1. Modulation of STAT5B isoforms by antisense oligonucleotides. 18m-anti and 19-anti bars above the transcripts 
indicate antisense splice-switching oligonucleotides. Blue arrows represent oligonucleotides for semi-quantitative RT-PCR analysis of 
splice-blocking. 
 





Current therapeutic strategies against STAT5B 
and other STAT proteins are predominantly based on 
inhibiting STAT functional domains such as DNA 
binding, cooperative binding (protein-protein inter-
actions), and dimerization/phosphorylation domains. 
Inhibition of these key domains not only halts pro-
to-oncogenic functions, but also inhibits tumor sup-
pressor actions of dominant-negative STAT5∆B, 
therefore diminishing the effectiveness of the therapy. 
To overcome therapeutic challenges, we developed a 
novel strategy based on endogenous mechanisms 
regulating STAT5B isoforms that utilizes a pro-drug 
capable of converting full length STAT5B (pro-
to-oncogenic) into the dominant negative truncated 
form of STATB (tumor suppressive). Therefore we 
applied specific steric-blocking splice-switching oli-
gonucleotides (SSOs) with a complimentary sequence 
to the targeted exon-intron boundary in the 
pre-mRNA of Stat5B to induce alternative in-
tron/exon retention enhancing production of tumor 
suppressor protein. The SSOs complementary to ex-
on/intron boundary sequences can block access of the 
spliceosomal machinery and stimulate retention of the 
associated exon [21-23]. They were used to alter 
splicing for therapeutic purposes in cell line models of 
human disease [21]. Splice-blocking oligonucleotides 
should bind specifically to target sequence while at 
the same time contain extra- or intra-molecular com-
plementarity, have suitable solubility, and do not bind 
too tightly (favoring off-target effects) or too loosely 
(causing low efficacy). The SSOs must be stable in 
serum, hybridize at a high melting temperature, and 
form duplexes with the targeted RNA, which are not 
processed by RNase H and/or other nucleases. This is 
usually achieved by 2’ modification of the sugar with 
O-methyl, O-methoxyethyl or O-aminopropyl groups 
or by backbone modifications such as in N3’ → P5’ 
phosphoroamidate, peptide nucleic acids (PNAs), 
phosphorodiamidate morpholino (PMO), or locked 
nucleic acids (LNAs) [24-26]. PNAs offer specificity 
similar to Morpholinos, but their low water solubility 
makes PNA experiments difficult. Morpholino oligos 
are usually soluble at several millimolar aqueous 
concentrations. We have chosen to use Morpholino 
oligonucleotides, which form stable base pairs with 
complementary nucleic acid sequences but do not 
bind proteins to a significant extent, and they mediate 
RNA cleavage by RNase H or the RISC (RNA induced 
silencing complex).  
In this work, we also developed quantitative 
PCR methodology to detect splice variants of STAT5B, 
providing a feasible solution to the significant chal-
lenge of separating nearly identical truncated forms of 
STAT5A and STAT5B. Here, we report evidence of the 
feasibility of implementing steric-blocking 
splice-switching morpholino oligonucleotides for the 
modulation of STAT5B isoforms.  
METHODS 
Tissue Culture 
Human PC-3 prostate cancer cells were obtained 
from American Type Culture Collection (Manassas, 
VA) and maintained in RPMI 1640 supplemented 
with 10% fetal bovine serum. 
Morpholino oligonucleotides and transfection 
Morpholino antisense oligonucleotides (m-anti) 
were purchased from Gene Tools, LLC (Philomath, 
OR, USA). They were delivered into PC-3 prostate 
cancer cells using Endo-Porter reagent (Gene Tools, 
LLC) as per manufacturer protocol. 
cDNA production 
Total RNA was isolated 24 hr post-treatment and 
reverse transcribed using an RNeasy Mini Kit 
(QIAGEN, CA) and SuperScript®IIIRT Reverse 
Transcriptase (Invitrogen, CA) according to recom-
mended manufacturer protocols. 
Sequence and analysis of DNA fragment. 
Sequence of RT-PCR fragments has been per-
forming in both directions by SeqWright DNA tech-
nology Services (Houston, TX). Alignment of se-
quences has been done by BLASTN 2.2.27 against 
NCBI nucleotide collection. 
TagMan probes for SPLICE and NONSPLICE 
variants of Stat5B 
Real-time PCR was performed via StepOne Re-
al-Time PCR System (ABI) utilizing self-designed 
TaqMan hydrolysis probes (SPLICE and 
NONSPLICE) and TaqMan-based ABI gene expres-
sion assays (Hs99999905_m1, Gapdh). All qPCR ex-
periments were performed in duplicate. Briefly, 
cDNA samples were introduced to a MicroAmp Op-
tical 48-well reaction plate (ABI), which was covered 
with MicroAmp 48-well Optical Adhesive Film (ABI). 
Each experimental well contained 20 µl total reaction 
volume and included 10 µl of TaqMan Universal PCR 
Master Mix (ABI), 1 µl of 20x TaqMan assay, 8 µl of 
water and 1µl of analyzed sample. Self-designed 20x 
assays (SPLICE and NONSPLICE) contained 16µМ 
each of forward and reverse primers and 5 µМ of 
TaqMan probe. The final PCR conditions were as fol-
lows: pre-heating at 50 °C for 2 min, denaturation at 
95°C for 10 min and 40 cycles of amplification and 
quantification (15 sec at 95 °C and 60 sec at 60 °C). 
Samples were normalized using Taqman based ABI 




gene expression assay Hs99999905_m1 for human 
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh, 
amplicon size = 122 bp). 
Sequence information for designing SPLICE and 
NONSPLICE splice variant primers and probes was 
obtained from NCBI NG_007271.1. For this project, 
SPLICE is considered a transcript variant without 
introns between exons 18 and 19 while NONSPLICE 
indicates the presence of the intron between exons 18 
and 19. TaqManTM probes, labeled at the 5’ end with 
FAM (6-carboxyfluorescein) and at the 3’ end with 
TAMRA (6-carboxytetramethylrhodamine), were 
synthesized via IDT. Primers and probes for TaqMan 
hydrolysis qPCR assays specific for each splice variant 
were designed using the Primer Express v3.0 program 
(ABI). For SPLICE (Figure 1), the forward (5’- 
CAGCGCCACGTACATGGAC -3’) and reverse (5’- 
CGAAGTCCCCATCGGTGTC -3’) primer sequences 
amplify a 75 bp region and probe (5’-FAM- 
AGGACTGAGTCAGGGTTCTGTGGGTACATGTTA
TAGT-TAMRA-3’) were designed to span the junc-
tions between exons 18-19. For NONSPLICE (Figure 
1), the forward (5’- GGCTTTCCCCTTCCCTTCA -3’) 
and reverse (5’- GAAGTCCCCATCGGTGTCAA -3’) 
primer sequences amplify a 75 bp region, and probe 
(5’-FAM- CTTTCCCTCCCAAGCCCTGACTCAGTC 
-TAMRA-3’) was designed to span intron-19 exon 
junctions. Primers and probes are specific to the input 
template as no other targets were found in selected 
NCBI Transcript Reference Sequences database. Du-
plex formation and secondary nucleic acid structures 
of primer sequences were also evaluated using Oli-
goAnalyzer 3.0 (Integrated DNA Technologies). The 
analysis of primers was performed by Primer-Blast, 
encompassed all homo sapien DNA sequences in the 
NCBI database, and showed only one specific product 
(http://blast.ncbi.nlm.nih.gov/).  
 To assess the efficiency of assays and assure va-
lidity of the ΔΔCT method, standard curves were 
prepared for serial dilutions of input cDNA for 
SPLICE, NONSPLICE and Gapdh (ABI, Hs 
999999016_m1) assays. All serial dilutions of human 
cDNA were prepared and run in triplicate. From the 
amplification curves, CT (Cq) values for each concen-
tration were determined and the slope of CT versus 
nanograms of cDNA was used to calculate the effi-
ciency of amplification (using StepOne software, ABI). 
TaqManTM assays were linear at 6 serial dilutions of 
cDNA (from 1 to 40 ng) and the efficiencies and cor-
relation coefficients (R2) were determined by the av-
erage of 2 independent experiments. For SPLICE, the 
slope was −3.16, R2 = 0.997, efficiency = 107.255, and 
for NONSPLICE slope was −3.223, R2 = 0.989, and 
efficiency = 104.305. For the gapdh assay (ABI, Hs 
99999905_m1) the slope =−3.246, R2 = 0.989, efficiency 
= 103.256. 
 In a separate validation experiment to confirm 
the validity of the ΔΔCT method, standard curves 
were analyzed for serial dilutions of input cDNA for 
SPLICE, NONSPLICE and Gapdh. The dilution series 
of cDNA containing the target gene of interest were 
analyzed by qPCR. The slopes of the dilution series 
were calculated by determining ΔCT between each 
point on the dilution series plotted against the log of 
sample (cDNA) input (mass). The rationale is that in 
performing ΔΔCT analysis, no or very minimal dif-
ference in efficiencies should exist between the gene 
of interest and the endogenous control (i.e. Gapdh) 
[27]. For each of these assays, the efficiency and R2 
values were appropriate and the slope of the line for 
ΔCT of Gapdh and targets (SPLICE and NONSPLICE) 
was less than 0.1. For qPCR analysis, each sample was 
run in triplicate. Each run included a control lacking 
template to test for contamination in assay reagents. 
After a 94 0C denaturation for 10 min, reactions were 
cycled 40 times with a 94 0C denaturation for 15 sec, 
and a 60 0C annealing for 1 min. Three types of con-
trols aimed at detecting genomic DNA contamination 
in the RNA sample or during the RT or qPCR reac-
tions were included: a RT mixture without reverse 
transcriptase, a RT mixture including the enzyme but 
no RNA, and a negative control (reaction mixture 
without cDNA template). The data were collected and 
analyzed using OneStep Software (ABI).  
Preparation of Whole Cell Extracts 
Cells were rinsed twice with ice-cold PBS (Invi-
trogen, Grand Island, NY), collected via cell scraper, 
and suspended in radioimmunoprecipitation assay 
buffer [50 mM NaF, 10 mM Na4P2O7, 0.5% sodium 
deoxycholate, 0.1% SDS, 1% NP40, 150 mM NaCl, 9.1 
mM Na2HPO4, and 1.7 mM NaH2PO4 (pH 7.4)] con-
taining the following protease and phosphatase in-
hibitors: 1 mM Na3VO4; 1 mM phenylmethylsulfonyl 
fluoride; 2 µg/ml aprotinin; 2 µg/ml antipain; 2 
µg/ml leupeptin; and 2 µg/ml benzamidine. After 
incubation at 4 °C for 30 min, cell extracts were iso-
lated by centrifugation and supernatants were col-
lected. Protein concentrations were measured using 
the Bio-Rad protein assay reagent (Bio-Rad, Hercules, 
CA). 
Western Blot Analysis 
Protein samples were separated by 7.5 % 
SDS-PAGE and transferred overnight to an Odyssey 
Nitrocellulose Membrane (LI-COR Biosciences). We 
routinely analyzed 60 µg of total cell lysate/lane. An 
antibody recognizing the amino terminus of STAT5 




(N-20) was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA), and ß-actin (AC-74) antibody 
was obtained from Sigma (St. Louis, MO, USA). After 
incubation with primary antibodies, the membranes 
were washed with PBS containing 0.1 % Tween 20 
(PBST) thrice. Membranes were further incubated for 
1 hr with IRDye800CW-conjugated goat anti-rabbit 
IgG and IRDye680-conjugated goat anti-mouse IgG 
secondary antibodies (LI-COR Biosciences) diluted in 
Odyssey Blocking Buffer. The blots were then washed 
three times with PBS-T and rinsed with PBS. Proteins 
were visualized by scanning the membrane using 
Odyssey Infrared Imaging System (LI-COR Biosci-
ences) for both 700- and 800-nm wavelengths.  
Cell Proliferation Assay 
Cell proliferation assays were performed using 
the colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymeth-
oxy-phenyl)-2-(4-sulfonyl)-2H-tetrazolium assay 
(CellTiter 96 AQ; Promega, Madison, WI) according to 
the manufacturer’s protocol. Cells were plated in 
96-well plates at a density of 2 x 103 cells/well. After 
transfection with SSOs, cells were grown for 12 hr in 
complete media followed by 36 hr in serum-free me-
dia.  
Clonogenic Assay 
24 hr after SSOs transfection in six-well plates, 
PC-3 cells were counted and re-plated in 100 mm 
dishes (200 cells/dish) for 10 days in complete me-
dium. Dishes were washed once with 0.85 M NaCl, 
stained with crystal violet (Sigma, St. Louis, MO, 
USA) dissolved in ethanol for 15 min, and washed 
well to remove excess crystal violet. Colonies con-
taining >50 cells were scored as positive. Each ex-
periment was performed twice in triplicates.  
Statistical Analysis 
 Values were expressed as the mean ± SE. Statis-
tical analyses were performed by Student’s t test for 
paired comparisons using StatView program (Abacus 
Concepts, Inc., Berkeley, CA, USA). Differences were 
considered statistically significant at P<0.05 and all 
experiments were performed independently twice or 
thrice. 
RESULTS 
Specific intron retention in Stat5B pre-mRNA 
by morpholino oligonucleotides in PC-3 cells 
PC-3 cells were treated with 
2’-O-methyl-modified oligoribonucleoside phos-
phorothioate with complimentary sequence to the 
targeted 5’ exon-intron boundary (18m-anti) and to 
the 3’ intron-exon boundary (19m-anti) in order to 
shift splicing patterns as shown in Figure 1 at con-
centration of 6 uM each. The sequences of 18m-anti 
and 19m-anti oligos are TGCCACCTAC/ 
TTCTGTGGGT and GAGTCAGGG/CTTGGGAGGG 
AAAGAA, respectively. Underlined is the 9 bp se-
quence of the 5’splice site, the slash indicates the ex-
on-intron boundary, and conserved nucleotides of 
splicing consensus are highlighted in bold. Scrambled 
mispared oligonucleotide (m-mis) RyrCACrryC-
TrCTyrGyyr was used as a negative control; where 
lower-case letters indicate mismatches, y – pyrimidine 
nucleotide; and r – purine nucleotide. Antisense se-
quences with mismatches were appropriately distrib-
uted along the sequence to provide a stringent and 
realistic assessment of sequence specificity.  
Figure 2 shows the transfection of PC-3 cells with 
steric-blocking splice-switching oligonucleotides. An 
induced shift in splicing of Stat5b isoforms is present 
(Figure 2). All targeted Morpholino oligonucleotides 
generated measurable amounts of predictable product 
at 559 bp confirmed by sequence analysis. These re-
sults demonstrate that the designed oligos are capable 
of enhancing intron retention. Furthermore, simulta-
neous introduction of both 18m-anti and 19m-anti 
oligos resulted in an increase of unspliced RT-PCR 
products (Figure 2, lane 4), suggesting that targeting 
splice-junctions blocked splicing events. Additionally, 
we observed that at high concentrations, even 
non-specific oligonucleotides (m-mis) cause a de-
crease in cell viability. RNA was isolated 24 hr 
post-treatment following reverse transcription. To 
validate the targeting procedure, the level and nature 
of transcript alteration was characterized by reverse 
transcriptase (RT)-PCR analysis of splice modification 
(18ex and 19ex, Figure 1). 
To validate the targeting procedure at lower 
concentration of SSO treatment, we designed a pro-
tocol utilizing Quantitative Reverse Transcriptase 
(RT) PCR analysis of splice modification using custom 
made TaqMan probes to detect splice variants of 
STAT5B (refer to Materials and Methods). This pro-
cedure detects measurable dose-dependent shift in 
splicing leading to the retention of specific introns. 
Next, we treated PC-3 cells with increased concentra-
tions of an equimolar mix of 18m-anti and 19-anti. 
Analysis of treated cells was performed on the total 
RNA isolated 24 hr post-treatment. Figure 3 shows the 
results of quantitative examination of total RNA by 
RT-PCR. Results demonstrate tuning of the ratio of 
non-spliced and spliced forms produced 
post-incubation with morpholino oligonucleotides. 
The quantity of STAT5B isoform expression and 
proportion of non-spliced vs. spliced forms increased 




after treatment by morpholino oligonucleotides. We 
observed a dose-dependent increase in splicing reten-
tion as indicated by a shift in the ratios of the corre-
sponding mRNA’s while mismatched oligo (m-mis) 






Figure 2. Agarose gel electrophoresis of semi-quantitative RT-PCR splice-blocking products. Splice-junctions were targeted 
with two splice-blocking Morpholino oligonucleotides as described. Lane 1: m-mis; 2: 18m-anti; 3: 19m-anti; 4: combination of 18m-anti 
and 19m-anti. M – 100 bp ladder. All targeted Morpholino oligonucleotides generated measurable amounts of predictable products 
indicating splice retention effect. (559bp). 
 
 
Figure 3. Effect of SSO’s treatment on quantity of transcription of Stat5B isoforms. The results of the analysis of total RNA 
by quantitative RT-PCR. Data demonstrate tuning of the ratio of non-spliced and spliced forms produced after treatment with morpholino 
oligonucleotides. Control (untreated) cells, m-mis- treatment with 600 nM mispared oligonucleotide, 30 nM, 100 nM, 300 nM, 600 nM - 
treatment with corresponding concentration of the mix of 18m-anti and 19m-anti. Error bars indicate mean ±SD (n=3). ♦, P = 0.002; ♦♦, 
P = 0.0008; ♦♦♦, P = 0.008; ♦♦♦♦, P = 0.0014; ∗, P = 0.0016; ∗∗, P =0.003; ∗∗∗, P =0.008; ∗∗∗∗, P =0.0003. 
 
 





Splice regulation by the SSOs induce produc-
tion of truncated dominant-negative isoform 
of STAT5 protein. 
 To analyze functional ability of splice blocking 
effects on protein expression, we performed Western 
blot analysis. Total protein levels from steric-blocking 
splice-switching oligonucleotide treated cells revealed 
an SSO-dependent increase in STAT5∆B protein 
production (Figure 4). These data are consistent with 
RT-PCR results and confirm that splice retention 
produces a functional transcript that can be efficiently 
translated into corresponding STAT5∆B protein. 
Inhibition of PC-3 cells proliferation and via-
bility by shifting STAT5B isoform toward 
truncated dominant-negative isoform. 
Previously, we reported that expression of a 
dominant-negative form of STAT5B reduces cell pro-
liferation and survival by blocking cell cycle progres-
sion [10, 11]. Our aim in manipulating splice switch-
ing to create the dominant-negative truncated form 
from the full form of STAT5B is to produce a potential 
tumor suppressor. We next analyzed effects of in-
duced splice switching by SSOs on cell proliferation 
and survival. We have observed dose dependent de-
crease of cell proliferation rate by SSOs treatment. 
Quantitative analysis of cell growth was determined 
by the application of different concentrations of SSOs 
to tumor cells (Figure 5) and indicated that 
splice-blocking oligonucleotides decrease the rate of 
cell proliferation. Colony formation assays (a hall-
mark of transformed and malignant cell potential 
[28]) revealed concentration dependent reduction of 
PC-3 cell viability following SSOs treatment (Figure 
6). To distinguish the toxicity of oligos to the cells 
from STAT5ΔB-mediated cell growth retardation, we 
treated cells with a mismatch morpholino oligonu-





Figure 4. Western Blot analyses of the splice blocking affect of morpholino oligonucleotides. Splice-junctions were targeted 
with two splice-blocking morpholino oligonucleotides as described above. m-mis – 600 nM of mis-pared oligonucleotide; 600 nM 300 nM, 
100 nM, and 30 nM corresponding concentration of combination of 18m-anti and 19m-anti; Un –untreated cells. 
 
 
Figure 5. Treatment with splice-blocking oligonucleotides decreases cell proliferation. Control – 600 nM of mispared oli-
gonucleotide; 600 nM, 300 nM corresponding concentration of combination of 18m-anti and 19m-anti. Error bars indicate mean ±SD 
(n=3). ∗, P = 0.009; ∗∗, P =0.0115. 
 





Figure 6. Reduction of cell survival by splice-blocking morpholino-oligonucleotides. Effect of splice blocking on cell viability as 
determined via clonogenic assay. Top panel shows images of representative plates treated with 600 nM morpholino oligonucleotides while 
the bottom panel quantitatively represents cell viability of SBM treated cells compared with untreated cells. M-mis - scrambled mispared 
oligonucleotide was used as a negative control for cell toxicity. Error bars indicate mean ±SD (n=3). ∗, P = 0.0075; ∗∗, P =0.007. 
 
 
DISCUSSION AND CONCLUDING 
REMARKS 
 Alternative splicing is quickly gaining momen-
tum as a viable target for molecular therapies [29]. 
STAT family of proteins is involved in many physio-
logical processes and participates in inflammatory 
responses and cancer progression. The problem with 
current approaches of therapeutic targeting of STAT 
proteins is simultaneous inhibition of opposite func-
tions of STAT isoforms. In this work we are present-
ing the design of the new approach to overcome this 
problem. 
 Splice-switching oligonucleotides are consid-
ered a novel class of therapeutics intended to induce 
therapeutically favorable splice variants of targeted 
genes [6]. The potential therapeutic benefit of anti-
sense oligonucleotides has been demonstrated by 
several reports [30-32]. Antisense Morpholino oligo-
nucleotides complementary to exon/intron boundary 
sequences can block access of the spliceosomal ma-
chinery and enhance alternative exon inclusion [23, 
33]. The demonstrated approach focused on induction 
of the specific splice retention that can occur naturally 
[4]. We have demonstrated that application of Mor-
pholino oligonucleotides to target exon-intron 
boundary in the pre-mRNA of Stat5B are able to in-
duce intron/exon retention, which was confirmed by 
semi-quantitative RT-PCR. . While limited delivery 
efficiency caused incomplete modification of splicing, 
all targeted Morpholino oligos generated measurable 
amounts of predicted target products at 559 bp (Fig-
ure 2). These results demonstrate that the designed 
oligonucleotides are capable of enhancing intron re-
tention (Figure 2). Additionally, quantitative RT-PCR 
analysis confirmed a dose-dependent shift in splicing 
leading to the specific intron retention (Figure 3) and 
our results indicate that a modified transcript with the 
additional exon can be efficiently translated into 
STAT5∆B protein (Figure 4). 
 Expression levels of STAT5∆B protein after en-
hancement was still significantly lower than the full 




length form. Although relative protein levels are 
lower, studies have previously demonstrated that the 
dominant-negative form has a significantly stronger 
impact on transcriptional regulation due to a slower 
rate of deactivation [4, 15]. Our cell culture data are 
consistent with previously reported observation re-
garding the tumor suppressor activity of STAT5∆B 
[10, 11]. Cell proliferation assays revealed that gener-
ation of the dominant-negative isoform of STAT5B by 
splice switching SSOs leads to a dose-dependent de-
crease in cell proliferation (Figure 5). In addition a 
clonogenic assay, which reflects the malignant poten-
tial of cancer cell lines, indicated a specific and sig-
nificant reduction in prostate cancer cell viability as 
induced by SSOs treatment (Figure 6). 
 These data demonstrate the feasibility of using 
specific steric-blocking splice-switching oligonucleo-
tides with a complimentary sequence to induce al-
ternative intron/exon retention to convert a pro-
to-oncogene (full length STAT5B) into a tumor sup-
pressor (dominant-negative truncated form of 
STAT5B) as a possible anti-tumor therapeutic strate-
gy. Moreover, alternative splice-switching oligonu-
cleotides inducing a switch from proto-oncogene to 
tumor suppressor functions could potentially be used 
for therapeutic tuning of other STAT proteins. 
  A common feature of most STATs is alter-
native splicing, which leads to generation of a domi-
nant-negative isoform. STAT proteins are involved in 
wide variety of physiological processes including 
immune response and tumor progression. Ability to 
modulate their actions and specifically switch func-
tion from tumor activating to tumor suppressing 
would be highly beneficial in many areas of biomed-
ical research. In conclusion we developed and con-
firmed a novel method to implement steric-blocking 
splice-switching oligonucleotides for targeted deliv-
ery towards the development of novel therapeutic 
strategies.  
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